FLIPR 6 Calcium Assay Kits provide a comprehensive method for detecting intracellular calcium changes in a simple and reliable homogeneous assay format. Combining the novel fluorophore with proven proprietary quench technology, the new assay affords the highest signal to background ratio. The unique dye is more resistant to anion-exchange proteins, enabling measurement with minimal to no probenecid, an exchange inhibitor, when studying cell lines containing an organic anion transporter.
Using a quench-free protocol, the FLIPR Calcium 6-QF Formulation allows assay performance without a masking technology, making it an ideal choice for quench-sensitive applications such as targets sensitive to quenchers or multiplexing with luminescent indicators. The new kits support GPCR targets that can be run on Molecular Devices’ FLIPR® Tetra and FlexStation® 3 Instrumentation.
Klaus Lun, Vice President of Product Marketing at Molecular Devices commented: “We are committed to providing a strong product pipeline, not only in instrumentation but also in reagents. The introduction of the new FLIPR 6 Calcium Assay Kits opens the door for researchers to assay the low-responding and more challenging targets. As we continue to move forward our goal is to enable researchers to screen more biorelevant assays and to further explore new assay dynamics including beat rate for cardiotoxicity studies. ”
Please visit www.moleculardevices.com/FLIPR_Calcium6 for more details and to request an evaluation sample
For high resolution image please email sarah.jeffery@zymecommunications.com
Contacts
Media contact:
Sarah Jeffery
Zyme Communications
T: +44 7771 730 919
E: sarah.jeffery@zymecommunications.com
Twitter: zymecomms
At Molecular Devices
Jennifer McKie
Vice President, Global Marketing
E: jennifer.mckie@moldev.com
T: +1 408 747 3514
About Molecular Devices, LLC
Molecular Devices is one of the world’s leading providers of high-performance bioanalytical measurement systems, software and consumables for life science research, pharmaceutical and biotherapeutic development. Included within a broad product portfolio are platforms for high-throughput screening, genomic and cellular analysis, colony selection and microplate detection. These leading-edge products enable scientists to improve productivity and effectiveness, ultimately accelerating research and the discovery of new therapeutics
Molecular Devices is committed to the continual development of innovative solutions for life science applications. The Company is headquartered in Silicon Valley with offices around the globe.
For more information about the complete product portfolio, visit www.moleculardevices.com
